Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder
Publication date
2013-01Author
Sutherland, Mark H.Gill, Jason H.
Loadman, Paul M.
Laye, Jonathan P.
Sheldrake, Helen M.
Illingworth, Nicola A.
Alandas, Mohammed N.
Cooper, Patricia A.
Searcey, M.
Pors, Klaus
Shnyder, Steven D.
Patterson, Laurence H.
Keyword
Animals; Antineoplastic agents; Metabolism; Pharmacokinetics; Pharmacology
; Biotransformation
; CHO cells
; Carcinoma; Transitional cell; Drug therapy; Enzymology; Pathology
; Cell line; Tumor
; Cell survival
; Cricetinae
; Cytochrome P-450 CYP1A1; Genetics
; Female
; Gene expression
; Humans
; Indoles
; Liver
; Maximum tolerated dose
; Mice
; Inbred BALB C
; Microsomes
; Pyrroles
; Tumor burden
; Urinary bladder neoplasms
; Xenograft model antitumor assays
; REF 2014
Peer-Reviewed
Yes